^
Association details:
| Biomarker: | RUNX1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Elzonris (tagraxofusp-erzs) (CD123 inhibitor, IL-3 antagonist, Elongation factor 2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia
Published date:
09/01/2020
Excerpt:
...RUNX1-mutated AML upregulate a pDC transcriptional program, poising the cells towards pDC differentiation and expansion. Finally, tagraxofusp, a targeted therapy directed to CD123, reduces leukemic burden and eliminates pDCs in a patient derived xenograft model. In conclusion, pDC-AML is characterized by a high frequency of RUNX1 mutations and increased expression of a pDC transcriptional program. CD123 targeting represents a potential treatment approach for pDC-AML.
DOI:
https://doi.org/10.1182/blood.2020007897
